Group 1 - OpenAI launched the ChatGPT Health feature on January 8, which aims to provide health-related answers, connect smart devices, and plan diet and exercise, similar to Alibaba's "Ant Aifu" [1] - The ChatGPT Health feature is expected to be rolled out to users in the coming weeks, as over 230 million health-related inquiries are made weekly on the platform [1] - Ant Group's "Ant Aifu" has already connected with 5,000 hospitals and 300,000 real doctors for online consultations, achieving 30 million monthly active users and over 10 million daily inquiries within a month of its launch [1] Group 2 - AI healthcare is gaining significant policy attention, with plans to create over 100 typical application scenarios by 2027 as outlined in the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry" [2] - The "Implementation Opinions on Promoting and Regulating the Application of 'Artificial Intelligence + Healthcare'" set development goals for 2027 and 2030, focusing on key applications, safety regulation, and organizational support [2] - Beijing's health commission aims for widespread AI product application in healthcare institutions by 2027 to ensure safety and increase effective supply [2] Group 3 - According to Grand View Research, the global AI healthcare market is projected to reach approximately $26.65 billion (about 186.1 billion yuan) in 2024 and is expected to soar to around $505.59 billion (about 3.5 trillion yuan) by 2033, with a compound annual growth rate of 38.8% [3] Group 4 - Over 30 AI healthcare-related concept stocks have been identified, with companies like Chuangye Huikang and Desheng Technology actively engaging with investors about their AI healthcare strategies [4] - Companies are integrating AI into healthcare services, with Chuangye Huikang promoting its "Huikang Cloud Hub" and Desheng Technology implementing "seamless payment" solutions in major hospitals [4] Group 5 - Institutions are closely monitoring innovations in the "AI + healthcare" sector, with companies like Runda Medical and Yuyupingmin launching AI-driven tools for clinical support [5] - A total of 12 concept stocks have received institutional research attention since Q4 2025, with significant interest in companies like Union Medical and Kairui Medical [5][6] - Kairui Medical plans to launch three new AI-integrated ventilators and masks in 2026, which will analyze sleep states and identify sleep events accurately [5]

Group 1 - The company and its subsidiaries obtained 9 domestic medical device registration certificates, 3 intellectual property qualifications, and 1 overseas qualification between October and December 2025 [1] Group 2 - The acquisition of these qualifications will enrich the company's product variety, enhance its intellectual property protection system, expand its product layout in the fields of tumor screening and precision diagnosis, and strengthen its core competitiveness [1]

Group 1 - The company and its subsidiaries obtained 9 domestic medical device registration certificates, 3 intellectual property qualifications, and 1 overseas qualification from October to December 2025 [1] - The acquisition of these qualifications will enrich the company's product variety, enhance its intellectual property protection system, expand its product layout in the fields of tumor screening and precision diagnosis, and strengthen its core competitiveness [1]

证券代码：688393 证券简称：安必平 公告编号：2026-001 广州安必平医药科技股份有限公司 关于自愿披露公司及子公司 2025 年 10-12 月获得 资质情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州安必平医药科技股份有限公司(以下简称"公司")及子公司在 2025 年 10-12 月获得国内医疗器械备案证 9 项、知识产权类资质 3 项，获得境外资质 1 项。相关信息如下： 一、获得资质的具体情况 | 序号 | 产品名称 | 证书编号 | 证书有效期 | 注册 | 所属技 | | --- | --- | --- | --- | --- | --- | | | | | | 分类 | 术平台 | | 1 | δ样蛋白 3(DLL3)抗体试剂 | 粤穗械备 | 2025.11-长期 | Ⅰ | IHC | | | （免疫组织化学法） | 20250583 | | | | | 2 | 基因缺 CSF1R/D5S23,D5S721 失探针试剂（荧光原位杂交 | 粤穗械备 | 2025.12-长期 | ...

广州安必平医药科技股份有限公司 2026 年第一次临时股东会会议资料 公司代码：688393 公司简称：安必平 广州安必平医药科技股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 1 月 | | | 广州安必平医药科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司股东会规则》以及《广州安必平医药科技股份有限公司章程》《广州安必平医 药科技股份有限公司股东会议事规则》等相关规定，特制定本会议须知： 一、为保证股东会的严肃性和正常秩序，除出席会议的股东及股东代理人、 公司董事、高级管理人员、聘任律师及董事会邀请的人员外，公司有权依法拒绝 其他人员进入会场。为确认出席会议的股东或其代理人或其他出席者的出席资 格，会议工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予 配合。 二、请出席会议的股东或其代理人或其他出席者准时到达会场签到并确认参 会资格。会议开始后，会议登记应当终止，由会议主持人宣布现场出 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Insights - The recent issuance of the "Guidelines for the Pricing of Pathology Medical Services" marks a new phase of standardization, normalization, and digital collaboration in China's pathology medical services [4] - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of digital slices, remote diagnosis, and intelligent analysis, which is expected to accelerate the digital transformation of the pathology discipline [4] - The refined pricing model is anticipated to enhance the medical pricing management system and incentivize medical institutions to invest in standardized construction and technological innovation in pathology services [4] Summary by Relevant Sections Industry Overview - The closing index is 8084.61, with a 52-week high of 9323.49 and a low of 6764.34 [1] Beneficiary Companies - Beneficiary companies include: - Anbiping, which has achieved full automation in specimen preparation, staining, and scanning, aligning with digital slice application requirements [5] - Aidesheng, focusing on core diagnostic solutions for various cancers with an automated reporting and data management system [5] - Zhongyuan Qihe, specializing in diagnostics for major diseases, providing comprehensive solutions through a combination of equipment, reagents, and services [5] - Maike Biology, which offers solutions for pathology diagnosis automation and intelligence [5] - Other notable companies in the ICL category include Jinyu Medical, Dean Diagnosis, Lanwei Medical, and Aidekang [5]

Core Insights - The National Healthcare Security Administration has officially issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)" which marks a new phase of standardized, regulated, and digital collaborative development in China's pathology medical services [1][2] Group 1: Policy Overview - The guidelines consolidate existing pathology medical service pricing projects into 28 core items, 3 additional charge items, and 2 expansion items, creating a clearer pricing framework [2] - The National Healthcare Security Administration will guide provinces to establish a unified price benchmark, allowing regions to adjust actual execution prices based on this benchmark [2] Group 2: Digital Transformation - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of new service models such as digital slides, remote diagnosis, and intelligent analysis [3] - This shift is expected to accelerate the transition of pathology from traditional manual operations to a fully digital process, making pathology data an important "data asset" in medical services [3] Group 3: Beneficiary Companies - Companies like Anbiping, which has automated workstations for specimen processing and supports digital slide applications, are well-positioned to benefit from this policy [4] - Aide Biology focuses on precision medical conditions and has developed an automated reporting and data management system, enhancing its capabilities in pathology services [4] - Zhongyuan Qihua provides comprehensive solutions for major diseases, integrating equipment, reagents, and services to support clinical medical institutions [4] - Maike Biology specializes in providing reagents, equipment, and technical support for pathology diagnosis, aiming for automation and intelligence in laboratory processes [4] - Other companies in the ICL category include Jinyu Medical, Dean Diagnostics, Lanwei Medical, and Aide Kang, which are also expected to benefit from the policy [4]

Core Viewpoint - Anbiping (688393) has experienced a decline in stock price and market capitalization, with significant shareholder reductions and developments in its business related to digital pathology and AI-assisted diagnostics [1][2][3]. Group 1: Stock Performance and Shareholder Changes - As of December 26, 2025, Anbiping's stock closed at 23.99 yuan, down 3.85% from the previous week [1]. - The total market capitalization of Anbiping is 2.217 billion yuan, ranking 121 out of 127 in the medical device sector and 5001 out of 5181 in the A-share market [1]. - From December 1 to December 30, 2025, major shareholders reduced their holdings by a total of 685,800 shares, representing 0.7329% of the company's total equity [2]. Group 2: Institutional Research Insights - The National Healthcare Security Administration's new guidelines on pathology services are relevant to Anbiping, particularly regarding digital slide scanning and case report uploads, which could incur penalties if not provided [3]. - Anbiping's cervical cytology product is currently in the registration process, with the potential for new revenue streams from auxiliary diagnostic services [3]. - The company has over 300 medical institutions collaborating on its scanning equipment as of the first half of 2025 [4]. Group 3: AI and Digital Tools in Diagnostics - The integration of AI in pathology diagnostics is expected to enhance efficiency, with previous tests showing a reduction in diagnosis time from 218 seconds per slide to 30 seconds [6][7]. - Anbiping plans to negotiate with local healthcare and pricing departments to implement new pricing structures for AI-assisted diagnostics [5][6]. - The company is also expanding its AI capabilities beyond cervical cytology, with ongoing projects in immunohistochemistry and fluorescence scanning [7]. Group 4: Company Announcements - Anbiping will hold its first extraordinary general meeting of 2026 on January 14, 2026, to discuss the election of a non-independent director [8]. - The company announced the resignation of two senior executives and the nomination of a new non-independent director candidate, pending shareholder approval [8].

Core Viewpoint - Anbiping's stock price has shown significant fluctuations, with a year-to-date increase of 41.20%, but a recent decline over the past 60 days, indicating potential volatility in the market [1][2]. Group 1: Stock Performance - As of December 31, Anbiping's stock price reached 24.30 CNY per share, with a trading volume of 19.08 million CNY and a turnover rate of 0.86%, resulting in a total market capitalization of 2.274 billion CNY [1]. - The stock has experienced a net outflow of 2.6093 million CNY from major funds, with large orders accounting for 1.22% of total purchases and 14.89% of total sales [1]. - Over the past five trading days, the stock has increased by 4.47%, while it has decreased by 8.92% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Anbiping reported a revenue of 253 million CNY, reflecting a year-on-year decrease of 28.29%, and a net profit attributable to shareholders of -10.77 million CNY, a decline of 136.34% [2]. - The company has distributed a total of 87.7965 million CNY in dividends since its A-share listing, with 36.4595 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, Anbiping had 7,567 shareholders, a decrease of 17.94% from the previous period, while the average number of circulating shares per person increased by 21.86% to 12,365 shares [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A holds 850,000 shares, with no change in the number of shares held compared to the previous period [3].

Group 1 - The core viewpoint of the news is that Anbiping's stock price increased by 1.01% to 24.04 CNY per share, with a total market capitalization of 2.249 billion CNY as of the report date [1] - Anbiping, established on July 6, 2005, and listed on August 20, 2020, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [1] - The revenue composition of Anbiping includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A Fund (200006) is among the top ten circulating shareholders of Anbiping, holding 850,000 shares, which represents 0.91% of the circulating shares [2] - The Longcheng Consumption Value Mixed A Fund has a current scale of 516 million CNY and has achieved a year-to-date return of 16.56% [2] - The fund's performance ranks 4905 out of 8085 in its category for the year, with a one-year return of 14.6% and a cumulative return since inception of 239.16% [2] Group 3 - The fund manager of Longcheng Consumption Value Mixed A Fund is Long Yufei, who has been in the position for 8 years and 77 days [3] - The total asset size of the fund managed by Long Yufei is 843 million CNY, with the best return during his tenure being 61.42% and the worst being -8.9% [3]